ReviewCritical care (London, England)2014
Treatment with echinocandins during continuous renal replacement therapy.
Review in Critical care (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Micafungin Sequestration and Late Release During Continuous Renal Replacement Therapy with Polyacrylonitrile- and Polysulfone-Derived Filters.Infectious diseases and therapy · 2026Article
- Antimicrobial dosing considerations in critically ill patients with acute kidney injury: A review.World journal of nephrology · 2025Review
- Invasive candidiasis in critical care: challenges and future directions.Intensive care medicine · 2020Review
- Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.Frontiers in pharmacology · 2020Review
- Adsorption and caspofungin dosing during continuous renal replacement therapy.Critical care (London, England) · 2019Article
- Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.Clinical pharmacokinetics · 2017Observational
- Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients.Critical care (London, England) · 2017Article
- Anidulafungin dosing during CRRT: do not underestimate adsorption!Critical care (London, England) · 2014Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Echinocandins are indicated as first-line treatment for invasive candidiasis in moderate to severe illness. As sepsis is the main cause of acute kidney injury, the combination of echinocandin treatment and continuous renal replacement therapy (CRRT) is common. Optimizing antibiotic dosage in critically ill patients receiving CRRT is challenging. The pharmacokinetics of echinocandins have been studied under various clinical conditions; however, data for CRRT patients are scarce. Classically, drugs like echinocandins with high protein binding and predominantly non-renal elimination are not removed by CRRT, indicating that no dosage adjustment is required. However, recent studies report different proportions of echinocandins lost by filter adsorption. Nevertheless, the clinical significance of these findings remains unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.